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Dr. Ralph M. Steinman, who discovered the dendritic cells 
(DCs) that play a key role in the adaptive immune response, was 
awarded the 2011 Nobel Prize in Physiology or Medicine 3 days 
after his untimely death.
1 Dr. Steinman used autologous DCs, 
cultured with tumor-specific antigens, to treat his own pancre-
atic cancer; the efficacy of this so-called “DC-based tumor vac-
cination” has recently been proven, and many researchers are 
now actively investigating this field. In contrast to the strategy of 
treating diseases by inducing active immunity, a strategy that 
involves suppressing unnecessary active immunity is required 
to avoid the development of autoimmune or allergic diseases, 
as these ailments occur due to failure to achieve immune toler-
ance to self or innocuous foreign materials. An article by Jang et 
al.,
2 which is published in this issue, demonstrates that Lacto-
bacillus rhamnosus prevents the development of asthmatic re-
actions by inducing immune tolerance via regulatory T (Treg) 
cells in a mouse asthma model. This study highlights the possi-
bility of preventing or treating asthma using cutting-edge im-
munological techniques.
Mechanisms of immune tolerance include the deletion of self-
reactive T cells in the thymus (central tolerance) and the dele-
tion, ignorance, anergy, inhibition, suppression, or deviation of 
the cells in peripheral organs (peripheral tolerance); Treg cells 
mediate immune suppression.
3 Since Sakaguchi et al.
4 first de-
scribed in 1995 that T cells expressing interleukin (IL)-2 recep-
tor α chain (CD25) are self-tolerant, it has been shown that the 
transcription factor forkhead box P3 (Foxp3) is a prerequisite 
for the development and function of immune suppression of 
such Treg cells. In fact, immune dysregulation, polyendocrinop-
athy, enteropathy, X-linked (IPEX) syndrome, a disease that 
arises due to a mutation in the Foxp3 gene, results in various se-
vere autoimmune and allergic diseases. As both innate and 
adaptive immunity work in response to bacterial infection, Treg 
cells come in two varieties: natural Treg (nTreg) cells, which are 
produced in the thymus, and adaptive or induced Treg (iTreg) 
cells, which are induced by antigen and transforming growth 
factor (TGF)-β, mainly in mucosal tissue.
5,6 nTreg cells make up 
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5%-10% of peripheral CD4
+ T cells and express CD4, CD25, and 
Foxp3 on their surface, but their IL-7 receptor (CD127) expres-
sion is low, and they develop early and play a primary role in 
self-tolerance. There are three types of iTreg cells: those that 
transform from peripheral naïve (CD4
+CD25
-Foxp3
-CD127
high) 
T cells by acquiring CD25 and Foxp3; Th3 cells (CD4
+CD25
-
Foxp3
- latency-associated peptide
+), which were discovered in 
1994 by a group researching the induction of oral tolerance and 
which secrete TGF-β;
7 and type 1 regulatory T cells (Tr1; CD4
+
CD25
-Foxp3
-), which were discovered in 2001 and which secrete 
IL-10 and TGF-β.
8
Immune tolerance is not simply the absence of an immune 
reaction to an antigen, but an active immune process that pre-
vents inappropriate immune responses. In healthy humans, 
Tr1 cells are generated in response to inhaled allergens in the 
presence of partially matured DCs or plasmacytoid DCs, and, 
thus, Tr1 cells are the dominant T cell subset in healthy persons, 
while Th2 cells dominate in allergic individuals.
9,10 The genera-
tion of Tr1 cells depends on DC-derived IL-10, IL-27, and TGF-β 
along with inducible costimulatory molecule (ICOS) signaling 
by DCs;
11 however, IL-10 expression is diminished in allergic 
airways.
12 Inhaled allergens induce indoleamine 2,3-dioxygen-
ase (IDO) in airway DCs, which catalyze tryptophan metabo-
lism to produce TGF-β, suppress IL-6, and promote the genera-
tion of Foxp3
+ iTreg cells.
11 Because the function, but not the 
number, of CD4
+CD25
+Foxp3
+ Treg cells in atopy and allergic 
rhinitis,
13 the number of Tr1 cells in allergic rhinitis,
14 and both 
the function and number of CD4
+CD25
+Foxp3
+ Treg cells all de-
crease in asthma,
15 and because the lung is normally a Th2-bi-
ased compartment,
10 atopic individuals develop allergic diseas-
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es via Th2 responses, instead of developing tolerance to innoc-
uous allergens. A recent study reported Foxp3 gene polymor-
phisms in allergic rhinitis.
16 IL-6 suppresses Foxp3 expression 
and iTreg cell generation to release the suppression of active 
immunity by Treg cells and induces Th17 cell differentiation, 
resulting in neutrophilic asthma.
6,10
Allergen-specific immunotherapy (SIT) is a well-known strat-
egy to develop immune tolerance to innocuous allergens that is 
naturally present in healthy persons and, thus, to modify the 
natural course of asthma. This treatment induces Tr1 cells
17 and 
Foxp3
+ iTreg cells
18 and thus suppresses pathogenic immune 
responses through secretion of IL-10 and TGF-β. In addition, 
sublingual immunotherapy (SLIT) may induce Th3 cells, as can 
be seen in oral tolerance.
19 The vitamin A metabolite retinoic 
acid, another agent that promotes the differentiation of Foxp3
+ 
iTreg cells, suppresses IL-6 production by DC and CD44
hi effec-
tor memory T cells that suppress TGF-β. Vitamin D (calcitriol) 
and glucocorticoid also induce Foxp3
+ iTreg cells by promoting 
TGF-β production by DC.
11 In addition, both calcitriol and glu-
cocorticoid convert CD4
+ T cells into Tr1 cells, and the effect by 
calcitriol, but not glucocorticoid, is associated with pro-
grammed death ligand (PDL)-1 expression in DCs.
20 CpG in-
duces Foxp3
+ iTreg cells by binding to Toll-like receptor (TLR) 9 
and activating IDO,
21 and bacille Calmette-Guérin vaccination 
induces those cells in association with ICOS signaling.
22
It has been thought that immune tolerance to inhaled aller-
gens in healthy persons, or when acquired after SIT in allergy 
patients, depends on Tr1 cells, not nTreg cells or Th3 cells, and 
that the transient expression of CD25 and Foxp3 in some iTreg 
cells may simply be a feature of activated effector T cells.
23 How-
ever, because allergy is severe in patients with IPEX syndrome, 
a disease due to a mutation in the Foxp3 gene, it is apparent that 
Foxp3 plays an important role in immune tolerance to allergens. 
In addition, CD25
+ T cells that are activated nonspecifically 
without allergen suppress Th2 cells,
24 and helminth infestation 
is associated with an increased number of Foxp3
+ Treg cells and 
a low prevalence of allergic diseases.
25 Therefore, nTreg cells may 
prevent allergic diseases in an allergen-nonspecific manner, 
but iTreg cells that develop after encountering allergens in the 
periphery mediate allergen-specific immune tolerance.
25 How-
ever, among self-reactive T cells, only cells expressing Foxp3 can 
survive when they receive T cell receptor (TCR) signals in the 
thymus,
26 and nTreg cells proliferate when their TCRs recognize 
a specific antigen to become antigen-specific Treg cells.
27 More 
importantly, Foxp3
+ iTreg cells can be induced by the above-
mentioned agents, including SIT;
11,18,21,22 consistent with this, 
Lactobacillus rhamnosus initiates immune tolerance to ovalbu-
min-induced allergic airway reactions by inducing Foxp3
+ iTreg 
cells, as presented later in this issue.
2
Intestinal commensal bacteria have an immunomodulatory 
effect, and reduction in gut probiotics, such as Lactobacillus or 
Bifidobacterium species, is associated with atopy.
28 In 1997, Ma-
jamaa and Isolauri
29 first introduced probiotics for treating al-
lergies by demonstrating that Lactobacillus GG ingestion for 1 
month significantly improved atopic dermatitis in infants. In 
2007, Feleszko et al.
30 demonstrated that oral administration of 
Lactobacillus rhamnosus GG or Bifidobacterium lactis for 8 
weeks to newborn mice suppressed asthmatic airway reactions 
in association with increased Foxp3
+ T cells in peribronchial 
lymph nodes. In addition, Forsythe et al.
31 showed that Lacto-
bacillus reuteri, but not Lactobacillus salivarius, attenuated 
asthmatic reactions, which was dependent on TLR9 and asso-
ciated with increased IDO activity. The beneficial effects of pro-
biotics seem to be strain-specific, and treatment may be most 
effective during the neonatal period. Orally administered pro-
biotics induce IL-10 production and IDO activation systemical-
ly, and thus suppress allergic reactions in the airways.
28 Treg 
cells induced by probiotics cause “bystander suppression” in 
an antigen-nonspecific manner, and create a regulatory milieu 
that promotes antigen-specific Treg cell production. Moreover, 
combined treatment with Bifidobacterium bifidum and SLIT 
using birch pollen extract has been shown to be superior to SLIT 
alone in inducing Foxp3
+ iTreg cells and suppressing asthmatic 
reactions.
32 Therefore, probiotic therapy for inducing immune 
tolerance to innocuous allergens is promising, but appropriate 
selection of the strain(s), administration timing, selection of 
subjects, and allergen-specificity, among other things, should 
be carefully considered.
As treatments using autologous iTreg cells expanded in vitro 
are actively pursued in the field of transplantation and autoim-
mune diseases, further investigations of such treatments for 
asthma and allergies are warranted. nTreg cells show complete 
demethylation in CpG motif methylation of the Foxp3 locus, 
conserved non-coding DNA sequence (CNS) 2 (formerly called 
the Treg cell-specific demethylated region [TSDR]),
33 and thus 
their Foxp3 expression is stable.
34 In contrast, iTreg cells show 
partial demethylation with TGF-β dependency, and thus their 
Foxp3 expression is unstable and progressively decreases over 
time. Therefore, to maintain the efficacy of Foxp3
+ iTreg cells, 
repeated induction of the cells should be done, or methods to 
stabilize their Foxp3 expression should be investigated. It has 
been reported that when Foxp3
+ iTreg cells are expanded in vi-
tro, their function is occasionally lost or they are converted into 
effector T cells, resulting in the opposite of immune tolerance,
35 
a problem that needs to be resolved. Because CD127 expression 
is high in effector T cells, but low in Treg cells, it has been sug-
gested that the combination of CD127 with other markers, such 
as CD25, may be useful for distinguishing between these T cell 
subsets.
36 However, there is still no apparent marker that can 
distinguish between Foxp3
+ iTreg cells and nTreg cells, even 
though the TCR repertoire and induction signal for development 
of the cells (i.e., CD28 and CTLA-4) differ between nTreg and 
Foxp3
+ iTreg cells.
26,34,35Immune Tolerance Induction
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